Representation and inclusion in clinical trials
Paving the way for inclusive clinical trials: establishing a platform for improvement
Advancements in AI for site selection
Learn how ICON is using human-enabled AI to efficiently integrate, interrogate and interpret large datasets from multiple sources and gain valuable insights for site selection in both expected and unexpected ways.
Equity and inclusion in rare disease clinical trials: beyond buzzwords
The rarity of each individual rare disease introduces many unique challenges and complexity in clinical research including barriers to achieving representative trial populations and equitable access to trials.
.png?crop=yes&w=982&h=600&a=938,0&itok=oNUPOHKs "11828-005-Front-Page-Banner_Subpage-banner_1-(1)"){kind=icon}
Inclusion in clinical trials whitepaper
Examining how the field of clinical research currently approaches inclusive enrolment gives us a baseline understanding on which we can build and make the necessary changes for improvement in the future. ICON looked at the barriers to accessing under-represented subgroups, the regulatory landscape and how organisations are addressing this issue and brings together the findings in this Whitepaper.
The promise of decentralised models and inclusion in clinical trials
ICON invited senior executives from Amgen, Sanofi, Eli Lilly and Janssen Research & Development LLC to discuss how decentralised and hybrid clinical trial models can provide increased resilience and how their respective organisations currently (or are likely to) address representation and inclusion in clinical trials into the future.
Representative clinical trials in a post-pandemic world
Inclusive clinical research has been a major topic of discussion for years, but it took the COVID-19 pandemic for the biopharma industry to fully realise the importance of recruiting representative populations into studies.
-
Media article: Shaping tomorrow: Today’s leaders are building a stronger, more inclusive future for the industry
In this article, Rose Kidd, President of Operational Delivery, discusses how greater support for women in leadership and research is helping to shape a stronger future for the pharma industry.
-
Media article: Girls see gender inequality as biggest barrier to pursuing Stem careers
Rose Kidd, President, Operations Delivery, provides an overview on how ICON is working to meet its gender balance ambitions in the Irish Times Life Sciences and Stem supplement.
-
Blog: Enhancing diversity in clinical trials
To fully assess the efficacy and safety of a therapeutic indication, clinical trials must evaluate populations that are representative of the treatment population, as different people may experience the same disease differently.
-
Blog: Enhancing diversity in clinical trials with AI and human expertise
Explore how AI-enabled insights and data-driven site selection can play a key part in a multifaceted approach to diversity in clinical trials and benefit equity in healthcare by extension.
-
Media article: Engaging minority communities: collaborative practises and long-term success
Rare diseases can disproportionately affect minorities, yet these communities are often underrepresented in clinical studies. ICON’s experts suggest ways to improve engagement and diversity.
-
Blog: Leveraging healthcare intelligence to increase diversity of oncology clinical trials
New regulatory requirements for diversity require sponsors to submit a diversity action plan alongside key trial documents to the FDA. Read the blog to learn how healthcare intelligence can be leveraged to increase diversity in oncology clinical trials.
-
Media article: Implications of regulatory and FDA guidance on diversity, equity and inclusion on clinical research study sites
Missy Gottschlich, Director of Site Networks for Accellacare, provides key insights on how sites can implement regulatory guidelines on diversity, equity and inclusivity.
-
Media article: Improving health equity and diversity throughout the life sciences
In this article, Joshua Bueller, Account VP and Senior Strategy Consultant at ICON, describes how pharma companies can gain a better understanding into the needs of underrepresented and underserved groups using a patient-centric, data-driven approach.
